Novartis Ophthalmics AG Gets Canadian License For Eye Disorder Treatment

Published: Jun 22, 2006

Novartis AG's (NVS) eye health unit received an exclusive license to sell Lucentis in Canada under an amended contract with Genentech Inc. (DNA). Novartis said Thursday Lucentis is used for the treatment of wet, age-related macular degeneration. The disorder is a major cause of central vision loss and is the leading cause of severe blindness in Canada for people who are more than 50 years old.

Back to news